Platinum Investment Management Ltd. Lowers Holdings in Vera Therapeutics, Inc. $VERA

Platinum Investment Management Ltd. trimmed its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 25.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 119,384 shares of the company’s stock after selling 40,367 shares during the period. Vera Therapeutics makes up about 1.4% of Platinum Investment Management Ltd.’s holdings, making the stock its 16th largest holding. Platinum Investment Management Ltd.’s holdings in Vera Therapeutics were worth $6,046,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares during the period. Los Angeles Capital Management LLC purchased a new position in Vera Therapeutics in the fourth quarter worth approximately $46,000. Quantbot Technologies LP purchased a new position in Vera Therapeutics in the second quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. grew its position in Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock worth $157,000 after acquiring an additional 639 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on VERA shares. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. The Goldman Sachs Group restated a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Vera Therapeutics Trading Up 1.8%

VERA opened at $34.26 on Friday. Vera Therapeutics, Inc. has a 52 week low of $19.07 and a 52 week high of $56.05. The business has a fifty day simple moving average of $37.02 and a 200-day simple moving average of $41.38. The firm has a market cap of $2.46 billion, a P/E ratio of -6.18 and a beta of 0.93. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period last year, the firm posted ($0.81) earnings per share. On average, equities analysts expect that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Insider Activity

In other news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total value of $679,690.00. Following the sale, the chief executive officer directly owned 216,744 shares in the company, valued at approximately $7,963,174.56. This trade represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.